LifeMD Q2 2026 Earnings: GLP-1 Shift Lifts Gross Margin but Deepens Losses

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3 million, down about 3.5% from $49.0 million a year earlier, while diluted loss per share from continuing operations widened to $0.16 from $0.09. For the quarter ended June 30, gross margin improved to approximately 89%, but higher acquisition spending and lower upfront collections pushed adjusted EBITDA from a profit to a loss. The company also materially reduced its full-year revenue and adjusted EBITDA guidance.

Core Earnings Data

Revenue declined as LifeMD continued moving weight-management patients from compounded medications to branded GLP-1 therapies. Pricing and product-mix decisions, including a $39 introductory offer, also reduced upfront revenue and cash collections.

Lower shipping and fulfillment costs, better provider efficiency, and continued scaling of the in-house pharmacy kept gross profit nearly flat despite the revenue decline. That benefit did not extend to operating profit because selling and marketing expenses remained elevated.

Comparisons are presented on a continuing-operations basis where applicable. WorkSimpli, divested in November 2025, is classified as discontinued operations for all periods presented. Adjusted EBITDA is a non-GAAP measure.

Subscriber and Product Trends

LifeMD ended the quarter with approximately 356,000 active subscribers, 20% more than a year earlier. Weight Management Program subscribers reached approximately 108,000, up from just under 100,000 at the end of Q1 2026, and recurring subscriptions generated approximately 84% of revenue.

The weight-management mix has changed substantially. Approximately 95% of new patients now start treatment with branded GLP-1 therapies, leading management to conclude that the transition away from compounded GLP-1 medications is effectively near completion. Following a pricing change, the proportion of new patients choosing multi-month packages rose from approximately 25% before the change to about 85% afterward.

Management expects longer-duration plans to support retention, lifetime value, and more predictable recurring revenue. In the near term, however, the transition has reduced upfront revenue and weighed on profitability.

Women’s Health acquisition costs declined, according to the company, and additional pharmacy products are scheduled to launch in the second half. LifeMD also began an exclusive telehealth co-marketing collaboration with Halozyme subsidiary Antares Pharma for XYOSTED, a once-weekly testosterone auto-injector.

Profitability, Cash Flow, and Balance Sheet

The higher gross margin was outweighed by operating expenses. Selling and marketing expense rose 27% year over year to $28.0 million, reflecting elevated customer acquisition costs earlier in the quarter, although it declined $1.8 million sequentially as LifeMD reduced acquisition spending. General and administrative expense fell 5% to $13.6 million due to lower employee, legal, and professional-service costs.

Operating cash flow from continuing operations was negative $6.9 million. In addition to the larger operating loss, working-capital movements contributed to the reversal: accounts payable used $3.5 million of cash in Q2 2026 after providing $8.6 million in the prior-year quarter.

LifeMD ended June with $25.1 million in cash, down from $36.8 million at the end of 2025. The company had no debt and had access to an undrawn $30 million revolving credit facility. Current assets totaled $42.1 million, compared with current liabilities of $46.6 million. Management expects lower marketing spending and a growing recurring rebill base to help cash balances increase through year-end.

2026 Guidance

LifeMD reduced its full-year outlook to reflect the GLP-1 transition’s greater-than-expected near-term impact and $2 million to $3 million of net XYOSTED launch costs. At the midpoint, full-year revenue guidance fell by about 7%, while the adjusted EBITDA midpoint moved lower by approximately $17.5 million.

The company still expects positive adjusted EBITDA for the second half as cost savings take effect and recurring subscriptions expand, although the Q3 range includes both a potential loss and a profit. Its Q4 outlook implies an annualized exit revenue run rate of approximately $250 million and, before estimated XYOSTED launch costs, approximately $22 million of annualized continuing adjusted EBITDA.

Risks Investors Should Watch

• Transition economics: Branded GLP-1 therapies and lower introductory pricing have reduced upfront revenue and cash collection. LifeMD must demonstrate that longer customer relationships eventually compensate for this near-term pressure.
• Profitability execution: Adjusted EBITDA moved from a $3.9 million profit to a $3.5 million loss, while full-year guidance was reduced substantially. The expected second-half improvement depends on cost savings and growth in recurring rebills.
• Cash conversion: Quarterly operating cash use, a declining cash balance, and current liabilities above current assets increase the importance of improving operating cash flow, even though LifeMD has no debt and retains access to its revolving facility.
• New-product spending: The XYOSTED launch is expected to carry $2 million to $3 million of net costs in 2026. Its contribution and the timing of other pharmaceutical, insurance, Medicare, employer, and enterprise partnerships remain important to the updated outlook.

Conclusion

LifeMD’s Q2 results showed that the move toward branded GLP-1 therapies and longer-duration subscriptions is reshaping the business but carrying a larger short-term financial cost than management initially anticipated. Gross-margin expansion and subscriber growth were offset by acquisition spending, weaker upfront collections, wider losses, and negative cash flow. The main test for the second half is whether lower marketing expense and a larger recurring revenue base can produce the profitability and cash improvement embedded in the revised guidance.